{"id":"W4220919246","doi":"10.1007/s00262-022-03159-8","title":"Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial","year":2022,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; London Health Sciences Centre; Centre Hospitalier Universitaire Sainte-Justine; University of Toronto; SickKids Foundation; Hospital for Sick Children","funders":"Merck KGaA; Pfizer","keywords":"Medicine; Refractory (planetary science); Cohort; Dosing; Avelumab; Adverse effect; Internal medicine; Open label; Surgery; Gastroenterology; Immunotherapy; Cancer; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000337306,0.000391304,0.0007871943,0.0004003904,0.0003337686,0.00006738499,0.0004746958,0.0001829729,0.001352578],"category_scores_gemma":[0.00007815914,0.0003079209,0.00005886436,0.0007444667,0.0001343946,0.0003710518,0.0001419974,0.0006175429,0.00001408376],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001376777,"about_ca_system_score_gemma":0.0006150982,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001957781,"about_ca_topic_score_gemma":0.0002478572,"domain_scores_codex":[0.9969192,0.0005081666,0.0008540276,0.0008000979,0.0004032946,0.000515182],"domain_scores_gemma":[0.9979891,0.0002727041,0.0005840168,0.000916741,0.0001483974,0.0000890856],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7837029,0.05653728,0.009476393,0.000005134124,0.0009262009,0.0002435416,0.002491381,0.00005895727,0.02117912,0.000009723638,0.0007251089,0.1246443],"study_design_scores_gemma":[0.8195078,0.07182349,0.09366057,0.00009833371,0.0002132357,0.00001356098,0.0003853505,0.00007241092,0.002467915,0.00004784706,0.01122024,0.0004892115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885624,0.005717189,0.000004213571,0.0009944714,0.00117502,0.002799303,0.0005532532,0.0000854298,0.0001087219],"genre_scores_gemma":[0.9935347,0.001262568,0.0002526831,0.0008305856,0.0001573728,0.001784623,0.001922806,0.0001027269,0.0001518775],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.124155,"threshold_uncertainty_score":0.9999373,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04644449388634191,"score_gpt":0.3459004374383967,"score_spread":0.2994559435520547,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}